A novel acylated insulin analog
US-2024374692-A1 · Nov 14, 2024 · US
Cation complexes of insulin compound conjugates, formulations and uses thereof
US9101596B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101596-B2 |
| Application number | US-201113012146-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 24, 2011 |
| Priority date | Jul 19, 2004 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An insulin compound coupled to a modifying moiety having a formula: —X—R 1 —Y-PAG-Z—R 2 (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R 1 or R 2 is a lower alkyl, optionally including a carbonyl group, and when R 1 is a lower alkyl, R 2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—.
First claim
Opening claim text (preview).
We claim: 1. A solid complex comprising: an insulin compound conjugate comprising an insulin compound conjugated to at least one modifying moiety, wherein the insulin compound is human insulin or an analog thereof, wherein said analog is a peptide that comprises an A chain and a B chain and wherein the B chain contains at least 29 amino acid residues, wherein the modifying moiety comprises from 2 to 10 PEG subunits (OCH 2 —CH 2 ) forming a PEG component coupled to a lipophilic com…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K38/28Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101596B2 cover?
- An insulin compound coupled to a modifying moiety having a formula: —X—R 1 —Y-PAG-Z—R 2 (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R 1 or R 2 is a lower alkyl, optionally including a carbonyl group, and when R 1 is a lower alkyl, R …
- Who is the assignee on this patent?
- Radhakrishnan Balasingam, Aggarwal Diti, Ferro Michelle, and 6 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).